# EDGAR Filing Document

**Accession Number:** 0001803948
**File Stem:** 0001104659-25-073787
**Filing Date:** 2025-8
**Character Count:** 7803
**Document Hash:** 75d15f2e9d581529a9b6c9507cfdd202
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-073787.hdr.sgml**: 20250804

**ACCESSION NUMBER**: 0001104659-25-073787

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250731

**FILED AS OF DATE**: 20250804

**DATE AS OF CHANGE**: 20250804

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Bradley Mark T.
- **CENTRAL INDEX KEY:** 0001803948

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35803
- **FILM NUMBER:** 251182450

**MAIL ADDRESS:**
- **STREET 1:** C/O ENDO INTERNATIONAL PLC
- **STREET 2:** FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD
- **CITY:** BALLSBRIDGE, DUBLIN
- **STATE:** L2
- **ZIP:** 00000
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mallinckrodt plc
- **CENTRAL INDEX KEY:** 0001567892
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981088325
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1226

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15
- **BUSINESS PHONE:** 353 1 6960000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Bradley Mark T.<br><sub>(Last) (First) (Middle)</sub><br>675 MCDONNELL BLVD.<br><sub>(Street)</sub><br>HAZELWOOD, MO 63042<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP, Chief Integration Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Mallinckrodt plc [ NONE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2025-07-31 |  | A |  | 4294 | A | <sup>(1)</sup> | 4294 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(2)(3)</sup> | 2025-07-31 |  | A |  | 57601 |  | <sup>(2)(3)</sup> | <sup>(2)(3)</sup> | Ordinary Shares | 57601 | $0.00 | 57601 | D |  |

---

### Footnotes:

(1) On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. At the Merger Effective Time (as defined in the Transaction Agreement), each share of Endo common stock held by the reporting person immediately prior to the Merger Effective Time automatically converted into the right to receive approximately $1.31 in cash and 0.2575 ordinary shares of the Issuer without interest and subject to applicable withholding.

(2) Effective at the Merger Effective Time, (i) each restricted stock unit in respect of Endo common stock ("Endo RSU") held by the reporting person immediately prior to the Merger Effective Time automatically converted into a restricted unit in respect of a number of ordinary shares of the Issuer ("Issuer RSU") determined in accordance with the formula set forth in the Transaction Agreement and (ii) each performance-based restricted stock unit in respect of Endo common stock ("Endo PSU") held by the reporting person immediately prior to the Merger Effective Time automatically converted into an Issuer RSU in respect of the number of ordinary shares of the Issuer determined in accordance with the formula set forth in the Transaction Agreement assuming the performance goals were achieved based on target performance.

(3) The Issuer RSUs will vest ratably on April 23, 2026 and April 23, 2027. Upon vesting, each Issuer RSU will be settled in ordinary shares of the Issuer at one share per Issuer RSU.

**Remarks:**
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.

**Signature:** /s/ Mark Tyndall, Attorney-in-Fact  
**Date:** 2025-08-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**